SecBot SecBot
8-K ·Filed May 5, 2026

PFE

PFIZER INC
NEUTRAL
Impact 4/10
Horizonweeks Processed6mo ago SEC0000078003-26-000053
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

The EPS beat and revenue upside are modest and guidance was reaffirmed, not raised, limiting upside. The sharp decline in COVID-19 product sales (-59% to -63%) continues to pressure headline growth, though the non-COVID portfolio is expanding. The Vyndamax patent settlement adds revenue stability through 2031. Watch for the PDUFA date on Padcev's expanded MIBC indication (Aug 17, 2026) and the Hympavzi priority review decision in Q2 2026 as potential catalysts.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$26.43
T+0 close · May 5, 2026 · via day close
Latest settled
−5.74%
T+60 · $24.91
Vs SPY
−8.21%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 5 $26.43entry
  2. T+1 · 7mo ago +0.23%α −1.16% · $26.49
  3. T+5 · 6mo ago −2.08%α −4.07% · $25.88
  4. T+20 · 6mo ago −3.31%α −8.27% · $25.55
  5. T+60 · 4mo ago −5.74%α −8.21% · $24.91

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Pfizer reported Q1 2026 Adjusted diluted EPS of $0.75, beating the $0.72 consensus by 4.2%, on revenue of $14.45B, which also exceeded the $13.80B estimate. Total revenue grew 5% YoY (2% operationally), driven by 22% operational growth in launched and acquired products, though GAAP net income fell 9% YoY to $2.69B due to higher costs and an unfavorable tax rate. Full-year 2026 guidance was reaffirmed, including revenue of $59.5-$62.5B and Adjusted EPS of $2.80-$3.00.

Key Financial Metrics

EPS
$0.75
est $0.72 · +4.2%
Revenue
$14.5B
est $13.8B · +4.7% · +5.0% YoY
Rating
beat
Guidance
$59.5 to $62.5 billion
maintained
Gross Margin
24.6%

Key Facts

  • Q1 2026 revenue of $14.45B, up 5% YoY (2% operationally), vs consensus of $13.80B
  • Adjusted diluted EPS of $0.75 beat consensus of $0.72 by 4.2%
  • GAAP reported diluted EPS of $0.47, down 10% YoY from $0.52
  • Full-year 2026 guidance reaffirmed: revenue $59.5-$62.5B, Adjusted EPS $2.80-$3.00
  • Launched and acquired products revenue grew 22% operationally YoY
  • COVID-19 product revenue declined sharply: Comirnaty -59%, Paxlovid -63% operationally
  • Non-COVID portfolio grew 7% operationally, excluding Comirnaty and Paxlovid
  • Completed exit of ViiV Healthcare investment, receiving $1.875B in proceeds
  • Vyndamax patent settlements extend U.S. patent expiry to June 1, 2031
  • No share repurchases in Q1 2026; $3.3B remaining authorization

Financial Impact

Q1 revenue beat consensus by ~$650M; EPS beat by $0.03; guidance unchanged

revenueepsguidance

Risk Factors

  • Continued decline in COVID-19 product revenue may pressure total revenue growth
  • GAAP net income declined 9% YoY due to higher costs and unfavorable tax rate
  • Adjusted cost of sales rose 31% YoY, compressing adjusted gross margin
  • R&D expenses increased 12% operationally, reflecting heavy pipeline investment
  • Tariff and drug pricing policy uncertainty (TrumpRx, MFN) could impact future revenue

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
44% bullish (36 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0000078003-26-000053
Document: pfe-20260505.htm0000078003-26-000053
Document: 0000078003-26-000053-index-headers.html0000078003-26-000053
Document: 0000078003-26-000053-index.html0000078003-26-000053
Document: 0000078003-26-000053.txt0000078003-26-000053
8-K Data (Synthetic)0000078003-26-000053

Track record

21 reports on PFE

Performance horizon

5 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +17.28% at T+60 after the Aug 4, 2026 report. 7 of 9 went positive at some point.

Filters
  1. Nov 3, 202614d ago 8-K Neutral 2/10 Entry $30.79 Now $28.86 −6.27% settles Feb 2
  2. Nov 3, 202614d ago 8-K Bullish 6/10 Entry $30.00 Now $28.86 −3.80% settles Feb 1
  3. Oct 30, 202619d ago Court Ruling Neutral 2/10 Entry $30.67 Now $28.86 −5.90% settles Jan 29
  4. Oct 23, 202625d ago Institutional Cluster Mixed 3/10 Entry $30.03 Now $28.86 −3.90% settles Jan 21
  5. Aug 13, 202613w ago Court Ruling Neutral 1/10 Entry $26.79 to $29.23 Now $28.86 +7.73% ▲ +9.11% +12.15% vs SPY
  6. Aug 12, 202613w ago Insider Buy Bullish 5/10 Entry $26.80 to $29.39 Now $28.86 +7.69% ▲ +9.66% +15.14% vs SPY
  7. Aug 12, 202613w ago Insider Cluster Bullish 6/10 Entry $26.80 to $29.39 Now $28.86 +7.69% ▲ +9.66% +15.14% vs SPY
  8. Aug 6, 202614w ago Insider Cluster Bullish 4/10 Entry $26.20 to $30.52 Now $28.86 +10.15% ▲ +16.49% +18.16% vs SPY
  9. Aug 5, 202614w ago Insider Buy Bullish 5/10 Entry $26.20 to $30.52 Now $28.86 +10.15% ▲ +16.49% +18.16% vs SPY
  10. Aug 5, 202614w ago Insider Cluster Neutral 3/10 Entry $26.20 to $30.52 Now $28.86 +10.15% ▲ +16.49% +18.16% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens Thu (12h 19m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 5, 2026